AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, will be added to the Russell 2000 and Russell 3000 indexes at the U.S. market open on June 29, 2026, as part of the first 2026 Russell reconstitution.

Rhea-AI Summary

AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, will be added to the Russell 2000 and Russell 3000 indexes at the U.S. market open on June 29, 2026, as part of the first 2026 Russell reconstitution.

Approximately $12.2 trillion is benchmarked to Russell U.S. indexes. The addition follows AtaiBeckley’s recent inclusion in the S&P Total Market, S&P Completion, and CRSP U.S. benchmark indexes, further broadening its visibility across major U.S. equity benchmarks.

Positive

• Addition to Russell 2000 and Russell 3000 effective June 29, 2026
• Exposure to index family benchmarking approximately $12.2 trillion in assets
• Follows inclusion in S&P Total Market, S&P Completion and CRSP U.S. indexes
• Index membership may broaden visibility with U.S. institutional and index-tracking investors

Negative

• None.

Argus Jun 25 session

+9.83% close to close Open Argus

Details

News Market Reaction – ATAI

In the Jun 25 session, ATAI gained 9.83%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.8% in the session following this news. A strong positive reaction aligns with ATA...

Analysis

The stock moved +9.8% in the session following this news. A strong positive reaction aligns with ATAI’s move into major benchmarks, expanding access to $12.2 trillion-benchmarked index capital. History shows mostly modest post-news moves; insider net selling could temper sustained enthusiasm.

Key Figures

Assets benchmarked: $12.2 trillion Russell 2000 constituents: approximately 2,000 equities Russell 3000 constituents: approximately 3,000 stocks +3 more

Assets benchmarked

$12.2 trillion

Assets benchmarked against Russell U.S. indexes referenced in the announcement

Russell 2000 constituents

approximately 2,000 equities

Number of small-cap U.S. equities in the Russell 2000 Index

Russell 3000 constituents

approximately 3,000 stocks

Number of U.S. equities in the Russell 3000 Index

U.S. equity coverage

98% of investable U.S. equities

Market-cap coverage targeted by the Russell 3000 Index

Index addition effective date

June 29

Effective date for ATAI inclusion in Russell 2000 and 3000

Phase 3 study

Phase 3 study of BPL-003

Late-stage program referenced as advancing in the announcement

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   Grant program launch

   24h Move

   +2.1%

   Launch of Patient Impact Grant Program supporting mental health non‑profits.

2. May 27

   Investor conferences

   24h Move

   +0.7%

   Announcement of participation in multiple June investor conferences and webcasts.

3. May 12

   Earnings and pipeline

   24h Move

   +2.7%

   Q1 2026 financials with cash runway and late‑stage pipeline timing update.

4. Apr 27

   Patient award recognition

   24h Move

   -6.3%

   Silver Award in 2026 Patient Participant Index for participant‑informed research.

5. Apr 08

   Clinical data update

   24h Move

   -0.8%

   Publication of BPL‑003 Phase 2a data showing rapid, durable antidepressant response.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

russell 2000® index, russell 3000® index, crsp® u.s. benchmark indexes, phase 3

4 terms

russell 2000® index financial

"AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index"

A stock market index that tracks the performance of roughly 2,000 publicly traded U.S. companies with smaller market values, representing the broader small-cap segment of the market. It matters to investors because it acts like a thermometer for smaller companies—used as a benchmark to compare fund performance, guide portfolio allocation, and gauge economic or market trends affecting growth-oriented, higher-risk firms.

russell 3000® index financial

"added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open"

A broad stock market index that tracks the performance of about 3,000 publicly traded U.S. companies of all sizes, acting as a wide-ranging snapshot of the U.S. equity market. It matters to investors because it serves as a common yardstick for the overall market’s health and is the basis for many index funds and investment strategies—think of it as a single basket that shows how the whole U.S. stock market is doing.

crsp® u.s. benchmark indexes financial

"additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026"

A family of U.S. stock-market yardsticks created by the Center for Research in Security Prices that track the performance of different slices of the American equity market (for example, the whole market, large companies, or small companies). They are built using transparent rules and weight companies by size so investors and fund managers can compare returns, judge active managers, or design index-tracking funds—think of them as calibrated thermometers and rulers for U.S. stocks.

phase 3 medical

"With our Phase 3 study of BPL-003 advancing, this development comes at an important time"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution
• The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked
• Inclusion expands AtaiBeckley’s visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026
  

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29^th as part of the first 2026 Russell indexes reconstitution.

Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. indexes, making it one of the most widely referenced index systems for institutional investors, index-tracking funds and active investment strategies. The Russell 2000® Index measures the performance of approximately 2,000 small-cap US equities, while the Russell 3000® Index measures the performance of approximately 3,000 stocks and includes all large-cap, mid-cap and small-cap US equities. The Russell 3000® Index is designed to represent approximately 98% of investable US equities by market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: “Joining the Russell Indexes - which collectively benchmark approximately $12.2 trillion in assets - represents another meaningful milestone for AtaiBeckley as we continue to expand our presence across the U.S. equity benchmark landscape, and increase visibility with a broad base of institutional investors. With our Phase 3 study of BPL-003 advancing, this development comes at an important time for the Company and reflects the maturity and strength of both our team and our late-stage mental health pipeline.”

The addition follows AtaiBeckley’s recent inclusion in the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes, which expanded the Company’s visibility across major U.S. equity benchmarks.

About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is in Phase 3 clinical development; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the expected impact of the inclusion on the indices; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; and the plans and objectives of management for future operations, research and development and capital expenditures.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our quarterly reports and other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com

Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does AtaiBeckley (NASDAQ: ATAI) joining the Russell 2000 Index mean for investors in 2026?

AtaiBeckley’s addition to the Russell 2000 adds the stock to a widely tracked small-cap benchmark. According to AtaiBeckley, Russell U.S. indexes have about $12.2 trillion benchmarked, which may increase visibility with institutional, index-tracking and active investors.

When will AtaiBeckley (ATAI) be added to the Russell 2000 and Russell 3000 indexes?

AtaiBeckley will join the Russell 2000 and Russell 3000 indexes on June 29, 2026, at the U.S. market open. According to AtaiBeckley, this occurs as part of the first 2026 Russell indexes reconstitution, aligning the company with key U.S. equity benchmarks.

How could Russell 3000 inclusion affect AtaiBeckley (ATAI) stock visibility and liquidity?

Russell 3000 inclusion places AtaiBeckley within a broad benchmark covering about 98% of U.S. equities. According to AtaiBeckley, approximately $12.2 trillion is benchmarked to Russell U.S. indexes, which may help expand visibility among institutional, index, and active investment strategies.

Why was AtaiBeckley selected for Russell indexes during the 2026 reconstitution?

FTSE Russell determines membership mainly using market-capitalization rankings and style attributes. According to AtaiBeckley, the company met criteria for inclusion in the Russell 2000 and Russell 3000 during the 2026 reconstitution, aligning it with small-cap and broad U.S. equity benchmarks.

How does Russell index inclusion relate to AtaiBeckley’s S&P and CRSP benchmark additions?

Russell index inclusion follows AtaiBeckley’s March 2026 additions to S&P Total Market, S&P Completion and CRSP U.S. benchmarks. According to AtaiBeckley, this sequence broadens the company’s presence across major U.S. equity benchmark families and may increase investor awareness.

What is AtaiBeckley’s business focus as it joins the Russell 2000 and 3000 indexes?

AtaiBeckley is a clinical-stage biotechnology company developing rapid-acting, durable and convenient mental health treatments. According to AtaiBeckley, its pipeline includes a Phase 3 study of BPL-003, and Russell inclusion comes as its late-stage mental health programs advance.